Immunoprecise Antibodies Shares Owned By Institutions vs. EBITDA
| IPA Stock | USD 0.41 0.03 7.89% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.85 | 0.4916 |
|
|
For Immunoprecise Antibodies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunoprecise Antibodies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunoprecise Antibodies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunoprecise Antibodies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunoprecise Antibodies over time as well as its relative position and ranking within its peers.
Immunoprecise |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunoprecise Antibodies EBITDA vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. Immunoprecise Antibodies is rated below average in shares owned by institutions category among its peers. It is rated fifth overall in ebitda category among its peers . At present, Immunoprecise Antibodies' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.Immunoprecise EBITDA vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Immunoprecise Antibodies |
| = | 6.50 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Immunoprecise Antibodies |
| = | (22.95 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Immunoprecise EBITDA Comparison
Immunoprecise Antibodies is currently under evaluation in ebitda category among its peers.
Immunoprecise Antibodies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunoprecise Antibodies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunoprecise Antibodies will eventually generate negative long term returns. The profitability progress is the general direction of Immunoprecise Antibodies' change in net profit over the period of time. It can combine multiple indicators of Immunoprecise Antibodies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 2 M | 2.1 M | |
| Operating Income | -13.8 M | -13.1 M | |
| Income Before Tax | -28.7 M | -27.3 M | |
| Total Other Income Expense Net | -14.9 M | -14.2 M | |
| Net Loss | -27.2 M | -25.8 M | |
| Income Tax Expense | -1.5 M | -1.4 M | |
| Net Interest Income | 4 K | 4.2 K | |
| Net Loss | -27.2 M | -25.8 M | |
| Net Loss | -23.9 M | -22.7 M | |
| Interest Income | 23 K | 21.9 K | |
| Change To Netincome | 3.8 M | 2.9 M | |
| Net Loss | (1.06) | (0.11) | |
| Income Quality | 0.16 | 0.58 | |
| Net Income Per E B T | 0.95 | 0.72 |
Immunoprecise Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunoprecise Antibodies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunoprecise Antibodies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunoprecise Antibodies' important profitability drivers and their relationship over time.
Use Immunoprecise Antibodies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunoprecise Antibodies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunoprecise Antibodies will appreciate offsetting losses from the drop in the long position's value.Immunoprecise Antibodies Pair Trading
Immunoprecise Antibodies Pair Trading Analysis
The ability to find closely correlated positions to Immunoprecise Antibodies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunoprecise Antibodies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunoprecise Antibodies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunoprecise Antibodies to buy it.
The correlation of Immunoprecise Antibodies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunoprecise Antibodies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunoprecise Antibodies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunoprecise Antibodies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immunoprecise Antibodies position
In addition to having Immunoprecise Antibodies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 206 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
To fully project Immunoprecise Antibodies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunoprecise Antibodies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunoprecise Antibodies' income statement, its balance sheet, and the statement of cash flows.